Printer Friendly
The Free Library
14,679,167 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Severe funding drought in biotech. (Up Front).


Biotech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 funding continues to be a struggle in the San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay.  region, one of the industry's most prominent and until recently prosperous regions.

The San Diego Tech Coast Angels, a local group of individual investors, said they plan to invest several million dollars in 10 early-stage local biotech firms over the next three years.

But entrepreneurs hoping to get funded can expect a tough screening process.

"We probably get four, five or six applications per month, (and) of those, we invest in one company every two or three months," said Charles Mathews Charles Mathews (June 28, 1776 - June 28, 1835) was an English theatre manager and comic actor, well-known during his time for his gift for impersonation. His play, At Home, in which he played every character, was the first monopolylogue and the defining work in the genre. , president of San Diego Tech Coast Angels.

Despite a flurry Flurry

A drastic volume increase in a specific security.
 of interest in new biotech funds, the venture funding climate remains bleak. Nationwide, first-quarter venture funding for biotechnology fell 40 percent this year from the like period a year ago. VentureWire, a newsletter, reported that only 10 of the 36 first-quarter biotechnology investments were first-time, or Series A, rounds.

In San Diego, standards for investing have also changed from a year or two years ago. "Everybody is looking for Looking for

In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with.
 a company that can move to revenue and cash break-even as quickly as possible," said Mathews.

"In 2001 we could still get a fair valuation," said Mark McWilliams, president and chief executive of Q3DM, a software maker focusing on analyzing data derived from microscopic microscopic /mi·cro·scop·ic/ (mi?kro-skop´ik)
1. of extremely small size; visible only by the aid of the microscope.

2. pertaining or relating to a microscope or to microscopy.
 testing.

"What people don't realize is for an entrepreneur to ask for money you have to have a sense for the market, and right now, it's probably the worst time in decades," he said.
COPYRIGHT 2003 CBJ, L.P.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:for the San Diego biotechnology industry
Author:Webb, Marion
Publication:Los Angeles Business Journal
Article Type:Brief Article
Geographic Code:1U9CA
Date:Apr 14, 2003
Words:249
Previous Article:Premium relief. (Health Care).(State Senator Liz Figueroa introduces bill to make health insurance premium hikes pass through state...
Next Article:DirecTV deal raises balance sheet concerns for Murdoch's fox brands. (Media & Technology).(New Corp. to acquire Hughes Electronics Corp.)
Topics:



Related Articles
Tech Funds Look Like Slackers Compared to Biotech.(Brief Article)(Statistical Data Included)
Biotech Struggles to Gain Healthy Returns on Research.(Brief Article)
FEEDING THE WORLD.(bietechnology could help the world hunger problem)(Brief Article)(Statistical Data Included)
Venturing Into a New Enterprise.(Brief Article)
The Council for Biotechnology Information has launched Biotech and You!, a new online magazine for information on food biotechnology.(Brief Article)
Betting on biotechnology: biotech funds may have a bright future ahead in spite of a down 2001. (Mutual Fund Focus).(Brief Article)
GVA launches new Life Sciences Group.(Brief Article)
Despite assets, valley cluster slow to develop.(BIOTECH: Uncertain Future in the Valley)
Turnaround appears on horizon for L.A. biotech funding.
Performance Plants receives largest private investment in Canadian ag biotech.(OFF THE WIRE)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles